do glp 1 cause kidney damage GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic disease Frontiers | GLP-1 Receptor Agonists
Description
Objective To determine whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with an increased risk of suicidal ideation, self-harm, and suicide among patients with type 2 diabetes compared with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 (SGLT-2) inhibitors
The problem with Ozempic isn't that it fails
A small human proof-of-concept trial reported that semaglutide reduced vastus lateralis cross-sectional area but did not reduce knee-extension strength or grip strength over 12 weeks
What hypothyroid patients should know about GLP-1 and GIP weight-loss medications like Wegovy (semaglutide) and Zepbound (tirzepatide)
Connect with certified providers on Meto for personalized support and results
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are peptide-derived analogs that were initially investigated to treat type 2 diabetes
